AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03258944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath-Stacking
Description: Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session.
Study NCT01142544 — intervention group
Intervention type: OTHER
Intervention: Evaluation oxygenation under standard ventilator settings
Description: Measure of PaO2 under standard FiO2-PEEP
Study NCT03753386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy simulation
Description: The intervention consists of reproducing oxygen therapy situations in healthy individuals by replacing oxygen bottles with bottles of air. A TeleOx® device will be placed on the circuit between the source and the nasal cannula for respiratory signals recording.~The intervention will last 30 minutes, containing the following activities in the given order:~* rest (9 minutes);~* drinking water (1 minute);~* rest (1 minute);~* coughing (1 minute);~* rest (1 minute);~* reading aloud (1 minute);~* rest (1 minute);~* breathing by the mouth (1 minute);~* rest (1 minute);~* exercising (running) (3 minutes) and~* rest (10 minutes)~Recordings will be retrieved after each test.
Study NCT01718119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-hCG
Description: r-hCG(250mcg) injection subcutaneously
Study NCT01718119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-hCG
Description: r-hCG(250mcg) injection subcutaneously
Study NCT02544204 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JVS-100
Description: Biological/Vaccine: JVS-100 Intramuscular Injection
Study NCT02544204 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Biological/Vaccine: Placebo Intramuscular Injection
Study NCT02482506 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MF-WLP
Description: The first meeting each week includes a 60-minute class that addresses health knowledge, attitudes, and self-monitoring of weight, food and physical activity; realistic goal setting; stimulus control; problem solving; cognitive restructuring and relapse prevention. Other class activities include weekly weigh-in; increasing awareness of portions by weighing and measuring foods; creating stimulus control plans for home, car and work; identifying barriers to healthy eating and/or exercise; going on a field trip to a local grocery store to practice reading food labels; creating an eating out management plan; and identifying high risk situations and brainstorming ways to manage them. This meeting also includes a 60-minute exercise class. The second meeting each week is a stand-alone 60-minute exercise class that will incorporate a variety of activities. A one-year CPD fitness club membership and home exercise DVDs will be provided.
Study NCT02482506 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SG-WLP
Description: Control participants will be provided with a 24-week weight loss curriculum; this includes a binder with their personal daily caloric recommendation, all intervention handouts, a copy caloric guidelines and useful weight loss tools. Upon randomization, each control participant will be introduced to the program materials and encouraged to tailor the weight loss program for themselves. The study team will call each control participant once a month during this 6-month program period to check in. In addition, after the follow-up data collection, control participants will receive a one-year membership to the CPD fitness center.
Study NCT03951571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Before breakfast, take an Anlotinib hydrochloride placebo once a day, 12 mg (1 pill) at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
Study NCT03951571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Before breakfast, take an placebo once a day, 1 pill at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
Study NCT02711397 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Comparison excretion levels of gluten immunogenic peptides
Study NCT03213522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Physical Therapy
Description: Educating the PFPT group on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
Study NCT03213522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Craniosacral Therapy
Description: Modified Upledger Institute 10-step protocol.
Study NCT01169493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VVI-40
Description: Pacing mode set to VVI-40, RV only pacing
Study NCT01169493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RV DDD-40
Description: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
Study NCT01169493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiV DDD-40
Description: ICD programmed to BiV pacing at a lower rate of 40
Study NCT02744690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC)
Description: Mitomycin-C is routinely applied to the eye prior to trabeculectomy at Menelik II Hospital
Study NCT03156725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Study NCT03156725 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aspiron
Study NCT00092222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 50 mg/m2 /day continuous intravenous infusion (CIVI) over 24 hours x 4 days (days 1-4) of 21 day cycle. A maximum of 6 cycles of R-EPOCH-R will be administered except in exceptional circumstances.
Study NCT00092222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-alpha
Description: Ages 18 and over: Initial dose of 7.5 million units subcutaneous, three times weekly x 14 days; subsequent dosesincrease dose as tolerated each 14 days to a maximum of 45 million units subcutaneous three times weekly; Ages 12-17: Initial dose of 5 million units/m2 subcutaneous, three times weekly x 14 days Subsequent doses: Increase dose as tolerated each 14 days to a maximum of 30 million units/m2 subcutaneous, three times weekly
Study NCT02237365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 81mg aspirin
Description: 1 tablet of 81mg aspirin and 2 tablets of placebo (visually matched to 500mg aspirin) daily for 60 days
Study NCT02237365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000mg aspirin
Description: 1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg aspirin daily for 60 days
Study NCT02237365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg placebo (visually matched to 500mg aspirin) daily for 60 days
Study NCT04304404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Cancer Risk Reduction Program (BrCaRRP)
Description: Women in the intervention group will complete the pre-tests electronically, and a 12-week intervention program will be implemented. The first meeting will be face-to-face individual training. In this training session, the risk of developing breast cancer will be calculated with each participant using breast cancer risk assessment tools. Modifiable and non-modifiable factors that increase breast cancer risk will be explained. With the participant, it will be decided which of the modifiable risk factors will be improved. Guidance will be given on topics such as genetic counseling, breast cancer screenings, increasing physical activity, healthy nutrition, weight control, smoking and alcohol use. The interventions will continue with phone calls and the 12-week program will be completed.
Study NCT01766765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jejunostomy
Description: Routine placement of jejunostomy tube following laparoscopic gastrectomy for gastric cancer. Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube
Study NCT01766765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early oral nutrition
Description: Free oral nutrition as tolerance allows on POD 1.
Study NCT04173403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 450mg AK102
Description: AK102 Q4W
Study NCT04173403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg AK102
Description: AK102 Q4W
Study NCT04173403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150mg AK102
Description: AK102 Q2W
Study NCT04173403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies
Study NCT00767299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arzoxifene
Description: 20 mg, QD, PO,24 weeks
Study NCT00767299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: QD, PO, 24 weeks
Study NCT02744690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin-C (MMC)
Description: Mitomycin-C is routinely applied to the eye prior to trabeculectomy at Menelik II Hospital
Study NCT01047436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinine
Description: 20 mg/kg intravenous quinine loading dose, followed by 10 mg/kg intravenously every 8 hours until resumption of normal oral therapy
Study NCT01047436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether
Description: Artemether sublingual spray 3 mg/kg at protocol specified timepoints until resumption of normal oral therapy
Study NCT04722263 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 15 Gy in 3 fractions
Study NCT04539262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV)
Description: Administered as an aerosolized solution
Study NCT03837197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kidney-Hypothermic oxygenated
Description: Kidney perfusion will be performed through the renal artery at 25-30 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (20 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 2 hours for kidneys.
Study NCT00515541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza
Description: First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily
Study NCT00006243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tyrosinase peptide
Description: Given SC
Study NCT00006243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1:27-35 peptide vaccine
Description: Given SC
Study NCT00006243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen
Description: Given SC
Study NCT00006243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given SC
Study NCT00006243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study NCT00006243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02447744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based intervention
Description: The intervention is an 8-week structured mindfulness based behavioral intervention program that teaches mindfulness meditation, mindful yoga and psychological knowledge about stress.
Study NCT04539262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as an aerosolized solution
Study NCT02447744 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness based intervention
Description: The intervention is an 8-week structured mindfulness based behavioral intervention program that teaches mindfulness meditation, mindful yoga and psychological knowledge about stress.
Study NCT04181749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin and atorvastatin
Description: Patients will be randomized and prescribed either no treatment or aspirin 75mg and Atorvastatin 40mg
Study NCT02724930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced facilitation of COPES
Description: Enhanced facilitation of COPES implementation consists of promotional meetings, automated case finding and proactive outreach to recruit patients, marketing and educational materials, local champion, and academic detailing.
Study NCT04539262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an aerosolized solution
Study NCT01008332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toleromune HDM
Description: ToleroMune HDM dose 1x4 administrations 4 weeks apart
Study NCT01008332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator, 1x4 administrations 4 weeks apart
Study NCT03659526 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Deformation imaging
Description: Deformation parameters derived using myocardial velocity imaging or speckle tracking
Study NCT00092222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV day 1, shall be administered prior to Doxil injection. When combined with EPOCH chemotherapy, Rituximab will be given on days 1 and 5.
Study NCT00092222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Cycle 1: Zidovudine 600 mg PO QID x 7-21 days in outpatient setting;600 mg PO q6hours x 7-21 (Intravenous zidovudine 300 mg q 6 hours may be substituted) days for inpatients; Cycle 2 and beyond: 600 mg PO QID x 7 days in outpatient setting; 600 mg PO q 6 hours x 7 days (300 mg q 6 hours may be substituted)
Study NCT00092222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Doxorubicin
Description: 21 day cycle; 20 mg/m2 Liposomal Doxorubicin given on day 1 and shall be administered after completion of Rituximab infusion from 2 to 6 cycles.
Study NCT02837861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine Nutritional Support plus supplemental IV amino acids
Description: Enteral nutrition as tolerated Plus supplemental IV AA infusion to meet the target of approximately 1.5-2.0gm protein/kg/day total starting within 24 hours of injury for 5 days.
Study NCT02837861 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Nutritional Support
Description: Enteral nutrition as tolerated.
Study NCT03820908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisantrene
Description: The patients will receive bisantrene 250mg/m2/d for 7 days in conjunction with the conventional supportive care.
Study NCT02725736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atosiban
Description: After random allocation to a treatment group, women will receive Atosiban as follows:~Atosiban was given as a single loading intravenous dose, 6.75 mg in 0.9% sodium chloride solution, followed by an intravenous infusion of 300 micrograms/min in 0.9% sodium chloride solution for the first 3 hours and then 100 micrograms/min for another 45 hours. The choice of the dose regimen for Atosiban was consistent with the recommendations of the product labeling.
Study NCT02725736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: After random allocation to a treatment group, women will receive Nifedipine as follows:~Nifedipine was given as a loading dose of 20 mg orally followed by another two doses of 20 mg, 20-30 minutes apart as needed. Maintenance was started after 6 hours with 20-40 mg four times a day for a total of 48 hours.
Study NCT03710694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAV132
Description: DAV132:~* Dosage: 15 g/day activated charcoal (22.5 g/day DAV132)~* Route: Oral~* Duration: duration of fluoroquinolone treatment + 2 days~DAV132 is regulated as a medical device in Europe and as a drug in the United States of America.
Study NCT00591162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Two courses of IV Tetracycline(10mg./kg./day for two days)separated by a two week interval.
Study NCT00591162 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Duel Energy X-Ray Absorptiometry (DEXA)
Description: DEXA before discharge from acute admission and again one year post burn.
Study NCT00591162 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Biopsy
Description: Bone biopsy to be taken in the operation room at the last skin grafting operation at the site of the iliac crest. A second bone biopsy will be taken one year later post discharge from the acute admission.
Study NCT03127462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led educational intervention
Description: Patients in the intervention group will receive an individual face-to-face conversation with a duration of 45 min. All patients will have access to telephone counselling by their primary nurse when needed and able to arrange a new face-to-face conversation. After 4-6 weeks the face-to-face the nurse will of conversation reach out to the patient by phone to follow up on the earlier conversation. Three months after the face-to-face conversation the nurse will offer the patient a closing face-to-face conversation of 15 min at the same time where the patient has a doctor appointment at the department. Those who are in the control group will continue standard care and not receive any conversation and be used as the control group.
Study NCT02635867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect Pulp capping-Resin-modified calcium silicate - TheraCal
Description: Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material
Study NCT02635867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect Pulp capping-Calcium hydroxide - Dycal
Description: Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
Study NCT02635867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect Pulp capping-Resin-based dentin bonding agent
Description: Use of a dental restorative protocol using resin-based dentin bonding system only
Study NCT02635867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Pulp capping-Resin-modified calcium silicate - TheraCal
Description: Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material
Study NCT02635867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Pulp capping-Calcium hydroxide - Dycal
Description: \\Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
Study NCT04207008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iBDecide Decision Support Application
Description: The iBDecide app provides an electronic tools to learn more about UC, track symptoms, create a nutrition diary, enter reminders for medication and clinic visits, as well as learn more about treatment options and compare UC medications.
Study NCT01712191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NUsurface Meniscus Implant
Study NCT00935662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8329
Description: Oral solution, single ascending doses
Study NCT00935662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution, placebo
Study NCT03885609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ToothWave
Description: RF-utilizing powered toothbrush for teeth whitening
Study NCT03885609 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: powered toothbrush
Description: regular powered toothbrush with no RF
Study NCT02169960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smart, Positive, Active, Realistic X-factor thoughts (SPARX)
Description: Cognitive Behavioral Therapy based online intervention for depression
Study NCT02169960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breaking Free
Description: Online based intervention for Drug and Alcohol Use